Adial PharmaceuticalsADIL
13F holders, Q2 2026 (June 30)17holders +2
4new positions
2sold out
1famous investor
$2.45avg. 13F price*
At the end of Q2 2026, 17 institutions reported holding Adial Pharmaceuticals Inc. (ADIL) in their 13F filings, up 2 from Q1 2026. 4 opened new positions and 2 sold out. The largest holders were Jane Street Group, LLC ($82K), Citadel Advisors ($76K) and UBS Group AG ($49K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Adial Pharmaceuticals Inc.
- CUSIP
- 00688A304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $214K |
| Exits | 2 | $34 |
All 13F filers, Q1 2026 → Q2 2026: 113,503 shares bought and 12,681 shares sold, net +100,822 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Jane Street Group, LLC | 0.00% | New | 32,119 | $82K |
| Citadel Advisors | 0.00% | New | 29,547 | $76K |
| UBS Group AG | 0.00% | Add +3432.7% | 19,147 | $49K |
| StoneX Group Inc. | 0.00% | New | 19,699 | $36K |
| Geode Capital Management, LLC | 0.00% | Reduce -48.9% | 12,393 | $32K |
| China Universal Asset Management Co., Ltd. | 0.00% | New | 8,000 | $20K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 5,879 | $15K |
| Vanguard Capital Management LLC | 0.00% | Add +1515.2% | 5,831 | $15K |
| Manchester Capital Management LLC | 0.00% | No change | 1,923 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +4.7% | 1,419 | $4K |
| BlackRock, Inc. | 0.00% | Reduce -72.6% | 304 | $778 |
| Raffa Wealth Management, LLC | 0.00% | No change | 83 | $212 |
| Morgan Stanley | 0.00% | No change | 50 | $128 |
| SBI Securities Co., Ltd. | 0.00% | No change | 47 | $120 |
| Wells Fargo & Company | 0.00% | No change | 6 | $15 |
| Harbour Investments, Inc. | 0.00% | No change | 3 | $8 |
| Abound Wealth Management | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is ADIL's weight in each manager's 13F, not the share of Adial Pharmaceuticals Inc. the manager owns.